PRESERVED-HF: Dapagliflozin improves physical limitations in patients with HFpEF
September 14, 2021
The SGLT2 inhibitor dapagliflozin boosted KCCQ scores and 6-minute walk distance in HFpEF patients in a 324-patient randomized trial.
At 18 months, much still unknown about diabetes and COVID-19
September 13, 2021
“COVID-19 has had a devastating effect on the population with diabetes.”
EMPEROR-Preserved spouts torrent of reports on empagliflozin treatment of HFpEF
August 31, 2021
The primary report from EMPEROR-Preserved on using empagliflozin to treat patients with HFpEF arrived with four other analyses published in its wake.
Dapagliflozin in HFrEF may cut arrhythmias, sudden death: DAPA-HF
August 27, 2021
Response to the positive findings was tempered, however, by the post hoc nature of the analysis, choice of primary outcome, and inconsistencies between key subgroups.
EMPEROR-Preserved: Empagliflozin scores HFpEF breakthrough
August 27, 2021
Empagliflozin is the first treatment to produce an unequivocal, hard-endpoint benefit in patients with heart failure with preserved ejection fraction, a practice-changing result.
U.S. kidney transplants grow in number and success
August 24, 2021
Data from 1996 to 2019 show more U.S. kidney transplants recently than ever before, and steady improvements in graft and patient survival.
SGLT2 inhibitor use rising in patients with DKD
August 23, 2021
Use of SGLT2 inhibitors in patients with type 2 diabetes rose sharply in 2019 and early 2020. GLP-1 RA use also showed recent gains.
Empagliflozin gets HFrEF approval from FDA
August 19, 2021
The SGLT2 inhibitor empagliflozin (Jardiance) becomes the second agent from this class to get a heart failure indication regardless of diabetes status.
Patients with diabetes more likely to be hospitalized, especially with foot infection
August 9, 2021
Participants with diabetes faced a 67% increased risk of infection-related hospitalization, compared with those without diabetes.
ESC heart failure guideline to integrate bounty of new meds
July 29, 2021
It has a simple answer to a seemingly complex issue: how to merge the newly approved with mainstay drug therapies. And it conditionally okays meds in a group long without guideline-directed options.